The flgr 242 peptide and PNC-27 represent a novel class of membrane-active research compounds engineered to target cell surfaces expressing human double minute 2 (HDM-2) protein. Preclinical assays demonstrate that these constructs selectively induce membrane perforation and rapid cell lysis in transformed cell models, bypassing conventional apoptotic signaling pathways.
The flgr 242 peptide and PNC-27 represent a novel class of membrane-active research compounds engineered to target cell surfaces expressing human double minute 2 (HDM-2) protein. Preclinical assays demonstrate that these constructs selectively induce membrane perforation and rapid cell lysis in transformed cell models, bypassing conventional apoptotic signaling pathways.
The flgr 242 peptide is a specialized membrane-active research compound investigated in preclinical oncology assays for its ability to target membrane-bound HDM-2 proteins on transformed cells. Unlike traditional research peptides that rely on intracellular signal transduction, FLGR 242 induces direct physical membrane disruption via rapid transmembrane pore formation, operating entirely independent of the wild-type p53 pathway.
Synthesized as a targeted structural variant within the broader family of HDM-2 binding peptide constructs, the FLGR 242 peptide allows laboratory investigators to study non-apoptotic pathways of cell death in transformed lines. In vitro assays indicate that its structural motif binds specifically to HDM-2 expressed on the outer cell membrane of cancerous cells, while demonstrating minimal interaction with non-transformed tissue membranes lacking surface HDM-2 complexing.
Research teams evaluating membrane dynamics, pore-forming kinetics, and targeted cytotoxicity utilize this compound alongside related control sequences like PNC-27 to map surface protein interactions and structural biophysics.
Both PNC-27 and FLGR-242 belong to a distinct category of chimeric, non-apoptotic membrane-active peptides. PNC-27 consists of an HDM-2-binding region derived from the p53 transcription factor (residues 12–26) coupled to a membrane-penetrating domain (such as penetratin or MRP-1 sequences). The FLGR 242 peptide alters or optimizes specific amino acid residues in the binding interface to evaluate target affinity and secondary amphipathic alpha-helical conformation.
In structural modeling, the physical conformation of these peptides dictates their ability to insert into lipid bilayers. While classical p53-mimetic peptides function by displacing p53 from cytosolic MDM2/HDM2 complexes to restore nuclear transcription, both PNC-27 and FLGR-242 utilize surface-localized HDM-2 as a anchor. Once bound to membrane-bound HDM-2, the hydrophobic tail of the peptide inserts directly into the phospholipid bilayer.
Comparative studies in cellular biophysics evaluate how minor sequence modifications between these two constructs alter micelle formation, oligomerization speed, and minimum effective concentrations required for complete membrane permeabilization.
Preclinical investigations demonstrate that the cytotoxic action of the FLGR 242 peptide is mediated through physical pore formation rather than metabolic toxicity or internal receptor signaling. Transformed cells frequently exhibit aberrant expression of HDM-2 on their extracellular plasma membrane, a phenomenon absent in non-transformed lines.
Upon administration in laboratory cell culture, the peptide's binding domain binds with nanomolar to micromolar affinity to extracellular HDM-2. This surface binding event concentrates the peptide on the target membrane surface. Upon reaching critical local density, the amphipathic domain inserts into the lipid matrix, causing local bilayer thinning and the formation of transmembrane pores measuring several nanometers in diameter.
Fluorescence microscopy and patch-clamp assays in preclinical studies show that these pores cause rapid loss of membrane potential, massive influx of extracellular calcium and water, and subsequent osmotic cell swelling followed by necrotic lysis within minutes of contact.
A critical focus of research involving membrane-active peptides is their functional independence from intracellular p53 status. A major challenge in preclinical oncology models is the high frequency of p53 mutations or deletions that confer resistance to standard apoptotic agents.
In vitro assays demonstrate that the FLGR 242 peptide retains equal lytic activity against p53-wildtype, p53-mutated, and p53-null cell lines. Because the mechanism relies entirely on surface receptor recognition and mechanical membrane destruction, internal signaling cascades, caspase activation, and mitochondrial outer membrane permeabilization (MOMP) are not required for cytotoxicity.
Data compiled across diverse transformed cell models—including solid tumor lines, leukemic blasts, and drug-resistant isolates—suggest that target sensitivity correlates primarily with surface HDM-2 density rather than underlying transcriptional or genomic alterations.
When designing comparative study protocols, researchers often evaluate several membrane-disrupting peptides within the same assay matrix. Below is a comparative overview of three principal research compounds in this structural class:
The PNC-27 construct serves as the foundational reference peptide, consisting of residues 12-26 of p53 linked to a cell-penetrating peptide sequence, demonstrating robust lytic activity across p53-mutated models. The FLGR 242 peptide provides altered physical-chemical properties designed for comparative structural studies of HDM-2 engagement and bilayer insertion kinetics. In parallel, PNC-28 features a similar p53-derived domain with altered terminal residue configurations to probe secondary structure stability during oligomerization.
Evaluating these three compounds side-by-side in high-throughput cell viability and lactate dehydrogenase (LDH) release assays allows investigators to map exact structural determinants of membrane insertion efficiency and target selectivity across varying membrane lipid compositions.
To characterize the kinetic profile of the FLGR 242 peptide, researchers utilize a standardized suite of analytical in vitro assays available across biomedical literature indexed in the PX1 Research hub.
Common testing protocols include:
• **LDH Release Assays:** Quantifies cytosolic enzyme leakage into culture media as a primary metric of physical cell membrane breakdown. • **Propidium Iodide / Trypan Blue Exclusion:** Assesses rapid changes in membrane permeability over time courses ranging from 15 minutes to 4 hours post-exposure. • **Scanning Electron Microscopy (SEM):** Provides visual confirmation of surface pore formation, membrane blebbing, and mechanical destruction of the lipid bilayer. • **Surface Plasmon Resonance (SPR):** Measures real-time binding kinetics (Kd, Ka, Kd) between the peptide sequence and immobilized recombinant HDM-2 extracellular domains.
Control protocols strictly incorporate non-transformed cell controls (e.g., primary human fibroblasts or untransformed epithelial lines) to confirm that membrane rupture is restricted to cells presenting surface-bound HDM-2.
Proper reconstitution and handling are essential to maintain the structural integrity and solution stability of the FLGR 242 peptide during experimental procedures. Like many amphipathic research peptides, improper solution preparation can lead to aggregation or non-specific binding to vessel walls.
• **Reconstitution:** Lyophilized vials should be brought to room temperature inside a desiccated cabinet prior to opening. Reconstitute using sterile research-grade water or buffered physiological solutions (such as sterile PBS, pH 7.4). For amphipathic sequences prone to self-association, gentle swirling without vigorous vortexing is recommended to prevent shear stress. • **Storage:** Lyophilized peptide powder should be stored at -20°C or -80°C for long-term stability. Once reconstituted into aqueous solutions, working aliquots should be used immediately or stored at -80°C to avoid repeated freeze-thaw cycles that disrupt peptide secondary structure. • **Vessel Selection:** Use low-protein-binding polypropylene microcentrifuge tubes and pipette tips to minimize surface adsorption during micro-volume assay preparation.
In preclinical peptide research, experimental reproducibility depends entirely on chemical purity and lot-to-lot consistency. Impurities such as truncated synthesis sequences, residual trifluoroacetic acid (TFA), or bacterial endotoxins can confound cell assay results, leading to false-positive cytotoxic readings.
PX1 Research enforces strict quality assurance standards across our full catalog of research peptides. Every lot of FLGR 242 peptide undergoes rigorous verification prior to distribution:
• **RP-HPLC Analysis:** Reversed-Phase High-Performance Liquid Chromatography establishes purity metrics, guaranteeing minimum thresholds of ≥98% purity. • **Mass Spectrometry (MS):** Electrospray Ionization (ESI-MS) or MALDI-TOF confirms exact molecular weight and sequence identity. • **Endotoxin Verification:** Chromogenic LAL testing verifies endotoxin levels remain below strictly controlled research thresholds (<0.01 EU/μg), protecting cell cultures from non-specific inflammatory responses. • **Lot-Specific Certificate of Analysis (COA):** Every shipped package includes comprehensive analytical documentation generated by an independent ISO 17025 accredited laboratory.
PX1 Research is a dedicated USA-based supplier of high-purity research compounds for academic institutions, biotechnology firms, and contract research organizations. All products are manufactured in GMP-compliant facilities within the United States, eliminating supply chain delays and international customs clearance complications.
Orders are fulfilled directly from state-of-the-art logistics hubs located in California and Arizona, offering same-day shipping for orders placed Monday through Friday before cut-off times. Academic laboratories and enterprise facilities requiring multi-gram quantities or recurring analytical supplies can establish a bulk lab account for streamlined procurement, dedicated account management, and bulk lot reservation.
What is the primary function of the flgr 242 peptide in research?
The flgr 242 peptide is a research compound studied for its ability to target membrane-bound HDM-2 on transformed cells and induce non-apoptotic, direct transmembrane pore formation leading to cell lysis.
How does FLGR 242 differ from PNC-27?
While both are membrane-active HDM-2-targeting peptides, FLGR 242 incorporates sequence modifications designed to evaluate variations in target affinity, amphipathic structure, and pore-forming kinetics relative to the standard PNC-27 sequence.
Is FLGR 242 activity dependent on the p53 pathway?
No. In vitro research demonstrates that FLGR 242 acts via mechanical disruption of the lipid bilayer following surface HDM-2 binding, functioning independently of intracellular p53 signaling or mutational status.
What cell surface marker does the flgr 242 peptide target?
Preclinical studies show FLGR 242 selectively binds to human double minute 2 (HDM-2) protein expressed on the outer cell membrane of transformed/cancerous cells.
How should FLGR 242 peptide be reconstituted for laboratory assays?
Reconstitute the lyophilized powder in sterile research-grade water or phosphate-buffered saline (PBS, pH 7.4). Avoid high-shear vortexing to prevent peptide aggregation, and use low-protein-binding polypropylene tubes.
What storage conditions are required for FLGR 242?
Lyophilized FLGR 242 should be stored at -20°C or -80°C. Reconstituted solution aliquots should be frozen at -80°C and protected from repeated freeze-thaw cycles.
What analytical testing is provided with PX1 Research peptides?
PX1 Research provides a lot-specific Certificate of Analysis (COA) for every batch, including RP-HPLC purity reports (≥98%), mass spectrometry molecular weight confirmation, and LAL endotoxin testing.
Can FLGR 242 be used in non-cancerous control cell lines?
Yes, non-transformed cells are frequently used as negative controls in FLGR 242 assays because they lack surface-bound HDM-2, demonstrating the compound's selectivity for target membranes.
Where is PX1 Research peptide manufacturing conducted?
All PX1 Research compounds are manufactured in USA-based, GMP-compliant facilities and tested in ISO 17025 accredited laboratories.
How fast does PX1 Research ship lab orders?
PX1 Research ships orders same-day Monday through Friday from facilities in California and Arizona.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.